BDSX
BIODESIX INCCompany Information
- Company Name
- BIODESIX INC
- CIK
- CIK0001439725
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- BDSX: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 08 Industrial Applications and Services
- SIC
- 8071
- SIC Description
- Services-Medical Laboratories
- Ticker
- BDSX
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-08-12
- Last sale
- 2026-02-23
- Shares purchased (TTM)
- 3,764,638
- Shares sold (TTM)
- 17,205
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 4,035,321
- Shares outstanding
- 10,296,000
- Ownership
- 39.19%
Earnings Market Reaction
- Filing date
- 2026-08-05
- Price on filing date
- —
- 1-month reaction
- 17.78%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 30 | 26 | 19 | 17 | 21 | 18 | 26 | 31 | 42 | 11 | 26 | 20 | ||||||
| Accounts Receivable Net Current | 9 | 10 | 9 | 13 | 7 | 8 | 9 | 8 | 10 | 10 | 8 | 6 | ||||||
| Other Assets Current | 4 | 6 | 4 | 4 | 4 | 4 | 5 | 5 | 5 | 7 | 6 | 3 | ||||||
| Assets Current | 44 | 41 | 33 | 33 | 32 | 30 | 39 | 44 | 58 | 28 | 40 | 29 | ||||||
Assets Noncurrent | ||||||||||||||||||
| Property Plant And Equipment Net | 24 | 24 | 25 | 25 | 26 | 27 | 28 | 29 | 28 | 29 | 28 | 25 | ||||||
| Intangible Assets Net Excluding Goodwill | 3 | 3 | 4 | 4 | 5 | 5 | 6 | 6 | 7 | 7 | 8 | 8 | ||||||
| Operating Lease Right Of Use Asset | 4 | 3 | 3 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Goodwill | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | ||||||
| Other Assets Noncurrent | 6 | 8 | 8 | 8 | 7 | 7 | 7 | 7 | 7 | 6 | 7 | 7 | ||||||
| Assets Noncurrent | 52 | 54 | 55 | 55 | 55 | 57 | 58 | 59 | 58 | 59 | 59 | 58 | ||||||
| Assets | 95 | 95 | 87 | 89 | 88 | 86 | 97 | 103 | 116 | 87 | 99 | 87 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 2 | 4 | 3 | 4 | 3 | 3 | 2 | 3 | 2 | 3 | 3 | 3 | ||||||
| Accrued Liabilities Current | 10 | 8 | 11 | 10 | 10 | 7 | 10 | 9 | 8 | 8 | 8 | 7 | ||||||
| Contract With Customer Liability Current | 0 | 0 | 1 | 3 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | ||||||
| Operating Lease Liability Current | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | ||||||
| Business Combination Contingent Consideration Liability Current | - | - | - | - | - | - | - | - | 6 | 19 | 22 | 19 | ||||||
| Notes Payable To Bank Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Other Liabilities Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 2 | ||||||
| Liabilities Current | 15 | 14 | 17 | 18 | 15 | 13 | 14 | 13 | 18 | 31 | 33 | 33 | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Long Term Notes Payable | 47 | 46 | 47 | 47 | 47 | 37 | 36 | 36 | 36 | 36 | 35 | 25 | ||||||
| Operating Lease Liability Noncurrent | 23 | 24 | 24 | 24 | 24 | 24 | 25 | 25 | 25 | 25 | 25 | 25 | ||||||
| Business Combination Contingent Consideration Liability Noncurrent | - | - | - | - | - | - | - | - | - | - | - | 5 | ||||||
| Other Liabilities Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Liabilities Noncurrent | 71 | 71 | 73 | 72 | 71 | 62 | 62 | 62 | 62 | 61 | 61 | 56 | ||||||
| Liabilities | 86 | 86 | 90 | 90 | 87 | 75 | 76 | 75 | 80 | 93 | 95 | 88 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 522 | 515 | 495 | 492 | 486 | 485 | 483 | 482 | 480 | 428 | 424 | 409 | ||||||
| Retained Earnings Accumulated Deficit | -513 | -506 | -498 | -494 | -485 | -474 | -462 | -454 | -444 | -433 | -420 | -410 | ||||||
| Stockholders Equity | 9 | 9 | -2 | -2 | 1 | 11 | 21 | 28 | 36 | -6 | 5 | -1 | ||||||
| Liabilities And Stockholders Equity | 95 | 95 | 87 | 89 | 88 | 86 | 97 | 103 | 116 | 87 | 99 | 87 | ||||||
| Allowance For Doubtful Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | ||||||
| Common Stock Shares Issued | 11 | 10 | 8 | 8 | 7 | 7 | 7 | 7 | 7 | 5 | 5 | 4 | ||||||
| Shares Outstanding | 11 | 10 | 8 | 8 | 7 | 7 | 7 | 7 | 7 | 5 | 5 | 4 | ||||||
| Stockholders Equity Note Stock Split Conversion Ratio1 | - | - | - | 0 | - | - | - | - | - | - | - | - | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialBIODESIX INC (BDSX) — SEC Financial Statements & Analysis
BIODESIX INC (BDSX) is a services-medical laboratories company, incorporated in DE. BIODESIX INC trades on Nasdaq as: BDSX. BIODESIX INC (BDSX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-05. Based on that filing, BIODESIX INC carries a market cap of $232.17M, a P/E ratio of -8.36x, a P/B ratio of 25.39x, a P/S ratio of 2.26x, an enterprise value of $248.91M, and an EV/EBITDA multiple of -16.56x. On profitability, it posts a gross margin of 115.07%, an operating margin of -20.02%, a net margin of -26.97%, a Return on Equity (ROE) of -540.01%, a Return on Assets (ROA) of -30.33%, and a Return on Invested Capital (ROIC) of -72.85%. Per share, it reports EPS of $-2.70, diluted EPS of $-2.70, free cash flow per share of $-1.97, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 34.46% year-over-year, net income growth of -32.42% year-over-year, and EPS growth of -51.87% year-over-year. On the balance sheet, it maintains a current ratio of 2.85x, a quick ratio of 2.85x, working capital of $28.27M, a debt-to-equity ratio of 9.42x, a debt ratio of 0.9, an interest coverage ratio of -2.55x, free cash flow of $-20.24M (TTM), and net debt of $16.73M. Figures sourced from SEC EDGAR.
- Market Cap
- $232.17M
- P/E TTM
- -8.36x
- EPS TTM
- $-2.70
- P/B TTM
- 25.39x
- ROE TTM
- -540.01%
- ROA TTM
- -30.33%
- Debt To Equity
- 9.42x
- Free Cash Flow TTM
- $-20.24M
- Net Revenue TTM Growth 1Y
- 34.46%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is BIODESIX INC in?
BIODESIX INC (BDSX) operates in the Services-Medical Laboratories industry.
What exchange does BDSX trade on?
BIODESIX INC (BDSX) trades on the Nasdaq.
Where is BIODESIX INC incorporated?
BIODESIX INC is incorporated in DE.
When was BIODESIX INC (BDSX)'s most recent SEC filing?
BIODESIX INC (BDSX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-05.
What is BDSX's market cap?
BIODESIX INC (BDSX) has a market capitalization of $232.17M as of 2026-06-30.
What is BDSX's EPS (earnings per share)?
BIODESIX INC (BDSX)'s trailing twelve month EPS is $-2.70 as of 2026-06-30.
What is BDSX's ROE (return on equity)?
BIODESIX INC (BDSX)'s trailing twelve month Return on Equity (ROE) is -540.01% as of 2026-06-30.
What is BDSX's ROA (return on assets)?
BIODESIX INC (BDSX)'s trailing twelve month Return on Assets (ROA) is -30.33% as of 2026-06-30.
What is BDSX's ROIC (return on invested capital)?
BIODESIX INC (BDSX)'s trailing twelve month Return on Invested Capital (ROIC) is -72.85% as of 2026-06-30.
What is BDSX's EV/EBITDA?
BIODESIX INC (BDSX)'s trailing twelve month EV/EBITDA is -16.56x as of 2026-06-30.